With 40% of Agentic AI Projects Predicted to Fail, Leading Software Developer Says Compliance Is the One Place Where Agentic AI Will Thrive
2.12.2025 01:01:00 CET | Business Wire | Press release
Ideagen's CEO explains why binary outcomes and high stakes make compliance ideal for autonomous AI
The CEO of one of the world’s leading global compliance software developers, Ideagen, has today (December 2, 2025) said compliance represents the one domain where autonomous AI will succeed – despite technology insights company Gartner® warning "… over 40% of agentic AI projects will be canceled by the end of 2027”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201511477/en/

Ben Dorks, Ideagen CEO
Speaking at the launch of their own agentic AI platform Ideagen Mazlan, Ben Dorks said: “Autonomous AI will succeed in compliance because failure is measurable, stakes are high and outcomes are binary.
“AI that continuously monitors jurisdictional or industry specific compliance frameworks, detects patterns across thousands of records, raises actions for others to follow, flags gaps before audits, autonomously? That's agentic. It will literally save lives and is the most transformative shift in protecting people, products and processes we have ever seen.”
Initial piloting has demonstrated significant acceleration in adoption and benefit, in some cases squeezing 30 minute-tasks down to just two minutes. More significantly, estimates show that enterprise level implementation that could take a company six to nine months, could be achieved in around 30 days.
“In the new year, we’ll be adding things like a voice interface so workers on the frontline, who might be in heavy PPE, can just tell Mazlan what’s happened,” said Dorks.
“And it’s intuitive, people won’t need to be trained to use it. If we can break down barriers to the adoption of digital solutions, then businesses are operating with better data which in turn results in the safer products and processes and a better return on that investment.”
Ideagen achieved the highest score for its AI integration in the 2025 Verdantix Green quadrant with Christopher Sayers, Senior Analyst at Verdantix stating: “Businesses seeking efficiency and safety improvements will find benefits in Ideagen’s pervasive use of AI.”
Ideagen Mazlan was also highlighted in Verdantix’s recent Future of AI-Enabled EHS Software Solutions: “These developments signal a broader shift towards AI that is not just assistive but increasingly capable of autonomously managing compliance and safety risks across complex environments.”
Dorks was also quick to stress that Ideagen Mazlan is not a bolt-on solution to increase productivity: “It’s intelligence, built in. Most 'agentic AI' isn't agentic at all – it's assistive AI with better marketing! AI that accurately answers questions when you ask them? That's a chatbot.
“Our agentic AI works on three simple principles: it's built into Ideagen solutions, it understands your specific industry context and appears naturally throughout your workflows.
“It knows OSHA, ISO and the legislation in your jurisdiction, it knows your own policies and data then uses this to analyze incidents, identifying risks, automating compliance tasks.
“But crucially, like autopilot technology on planes, we’ve built it to ensure that the power still sits with the human. Final oversight and approval remains with the quality managers and health and safety teams, but Mazlan is autonomously doing the heavy lifting.
“I’ll be honest, we could have gone further, but the world isn’t ready for that yet, agentic AI still needs to earn humanity’s trust before we give it full control. But what it can do to keep workplaces safe, reduce product recalls, keep supply chains moving, prevent harmful contaminants entering food? It’s mind blowing.”
Ideagen is one of the world’s leading providers of governance risk and compliance software (GRC) offering the widest spectrum of compliance solutions of any provider covering health and safety, quality, risk, audit, productivity and environmental monitoring.
Its customers include 75% of the top global pharmaceutical companies, more than 250 airlines, nine of the top 10 global aerospace and defense corporations, more than a third of the world’s automotive companies, nine of the top 10 global accounting firms, 65% of the world’s top food and beverage brands and over 2,000 government organizations, hospitals and healthcare centers.
Find out more about Mazlan at Ideagen.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20251201511477/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
Canva Announces Anthropic Collaboration to Bring AI-Powered Design to Millions17.4.2026 17:51:00 CEST | Press release
New collaboration brings Canva into Claude Design by Anthropic, turning AI-generated ideas into fully editable, on-brand designs Canva, the world’s leading all-in-one visual communication platform, today announced the next chapter in its two-year strategic collaboration with Anthropic, bringing Canva directly into the newly launched Claude Design by Anthropic Labs, one day after unveiling Canva AI 2.0 to a crowd of 6,500 people at Canva Create in Los Angeles.. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260410843169/en/ Canva and Claude Canva is also today introducing HTML importing, a new capability that makes it easy to bring interactive content generated in tools like Claude into the Canva editor for drag-and-drop collaboration, refinement, and publishing. The collaboration makes it easier for Claude Design users to turn AI-generated drafts and ideas into fully editable designs in Canva, where they become collaborative
Andersen Consulting tilføjer samarbejdsfirmaet Nuvolar17.4.2026 15:43:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform for digitale transformation gennem en samarbejdsaftale med Nuvolar, et teknologikonsulenthus med speciale i cloudbaseret softwareudvikling og avancerede Salesforce-implementeringer. Nuvolar, der blev stiftet i 2008 og har hovedsæde i Spanien, leverer end-to-end digital produktudvikling med dyb ekspertise inden for Salesforce, specialudviklede web- og mobilapplikationer, full-stack udvikling, UX/UI-design, produktledelse og langsigtede supporttjenester. Med mere end 110 fagfolk fordelt over Barcelona, Madrid, Miami og Mexico City arbejder virksomheden med kunder inden for luftfart, sundhedsvæsen, forbrugsgoder, medicinalindustrien samt hotel- og restaurationsbranchen for at designe og implementere skalerbare, forretningskritiske platforme, der optimerer driften og fremskynder den digitale transformation. "Samarbejdet med Andersen Consulting giver os mulighed for at levere vores ekspertise i en større skala," udtalte Marc Vivas, administrerende di
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom